Late lines of treatment benefit survival in metastatic breast cancer in current practice?

Breast

Volumn 20, Issue 6, 2011, Pages 574-578

  Planchat, E ^a,b,c,d   Abrial, C ^a,c,d   Thivat, E ^a,c,d   Mouret Reynier, M A ^a,b,c,d   Kwiatkowski, F ^a,c   Pomel, C ^a,b,c   Wang Lopez, Q ^a,b,c   Chollet, P ^a,b,c,d   Nabholtz, J M ^a,c   Durando, X ^a,b,c,d  

^a CENTRE JEAN PERRIN   (France)

^b UNIVERSITÉ CLERMONT AUVERGNE   (France)

^c Centre d'Investigation Clinique   (France)

^d INSERM   (France)

Author keywords

Chemotherapy; Metastatic breast Cancer; Overall survival; Tumor Response

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CAPECITABINE; CARBOPLATIN; CISPLATIN; FLUOROURACIL; GEMCITABINE; NAVELBINE; TAXANE DERIVATIVE; TRASTUZUMAB; VINCRISTINE;

ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER PATIENT; CANCER SURVIVAL; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG RESPONSE; DRUG TREATMENT FAILURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT ASSESSMENT; PRIORITY JOURNAL; SURVIVAL TIME;

EID: 82955248028     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2011.07.010     Document Type: Article

References (25)

1. Giordano S.H., Buzdar A.U., Smith T.L., Kau S.W., Yang Y., Hortobagyi G.N. Is breast cancer survival improving?. Cancer 2004, 100:44-52.
2. Coley H.M. Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. Cancer Treat Rev 2008, 34:378-390.
3. O'Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. Oncologist 2005, 10(Suppl. 3):20-29.
4. Tkaczuk K.H. Review of the contemporary cytotoxic and biologic combinations available for the treatment of metastatic breast cancer. Clin Ther 2009, 31(2):2273-2289.
5. Cardoso F., Di L.A., Lohrisch C., Bernard C., Ferreira F., Piccart M.J. Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades?. Ann Oncol 2002, 13:197-207.
6. Crivellari D., Galligioni E., Frustaci S., Foladore S., Lo Re G., Morassut S., et al. Cisplatin and mitomycin C in advanced chemotherapy-refractory breast cancer. Tumori 1990, 76:234-237.
7. Henderson I.C., Allegra J.C., Woodcock T., Wolff S., Bryan S., Cartwright K., et al. Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. J Clin Oncol 1989, 7:560-571.
8. Tacca O., LeHeurteur M., Durando X., Mouret-Reynier M.A., Abrial C., Thivat E., et al. Metastatic breast cancer: overall survival related to successive chemotherapies. What do we gain after the third line?. Cancer Invest 2009, 27:81-85.
9. Yamaguchi Y., Ohro S., Yamashiro Y., Shibata S., Ishiguro M., Yurugi E., et al. Role of palliative chemotherapy and shift from anticancer therapy to palliative care in patients with advanced or recurrent breast cancer. Gan to Kagaku Ryoho 2010, 37:65-69.
10. Chia S.K., Speers C.H., D'Yachkova Y., Kang A., Malfair-Taylor S., Barnett J., et al. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer 2007, 110:973-979.
11. Gueth U., Huang D.J., Schoetzau A., Holzgreve W., Wight E. Systemic therapy of metastatic breast cancer: the truth beyond the clinical trials. Oncology 2009, 76:247-253.
12. Cortes J., O'Shaughnessy J., Loesch D., Blum J.L., Vahdat L.T., Petrakova K., et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 2011, 377:914-923.
13. Coates A.S., Stockler M., Wilcken N. Controversies in metastatic breast cancer: optimal duration of chemotherapy ASCO Annual Meeting 2003.
14. Bastit P., Roche H., Namer M. Final results of a randomized trial comparing three epirubicin based regimens as first line chemotherapy in metastatic breast cancer (MBC) patients (PTS). Proc Am Soc Clin Oncol 1999, 18:128.
15. Gregory W.M., Smith P., Richards M.A., Twelves C.J., Knight R.K., Rubens R.D. Chemotherapy of advanced breast cancer: outcome and prognostic factors. Br J Cancer 1993, 68:988-995.
16. Porkka K., Blomqvist C., Rissanen P., Elomaa I., Pyrhönen S. Salvage therapies in women who fail to respond to first-line treatment with fluorouracil, epirubicin, and cyclophosphamide for advanced breast cancer. J Clin Oncol 1994, 12:1639-1647.
17. Kataja V., Castiglione M. Locally recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008, 19(Suppl. 2:ii):11-13.
18. Hortobagyi G.N., Buzdar A.U. Present status of anthracyclines in the adjuvant treatment of breast cancer. Drugs 1993, 45(Suppl. 2):10-19. discussion 18-19.
19. Hortobagyi G.N., Buzdar A.U. Current status of adjuvant systemic therapy for primary breast cancer: progress and controversy. CA Cancer J Clin 1995, 45:199-226.
20. Ackland S.P., Anton A., Breitbach G.P., Colajori E., Tursi J.M., Delfino C., et al. Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: a randomized multinational study. J Clin Oncol 2001, 19:943-953.
21. Du X.L., Xia R., Liu C.C., Cormier J.N., Xing Y., Hardy D., et al. Cardiac toxicity associated with anthracycline-containing chemotherapy in older women with breast cancer. Cancer 2009, 115:5296-5308.
22. Seidman A.D., Reichman B.S., Crown J.P., Yao T.J., Currie V., Hakes T.B., et al. Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response. J Clin Oncol 1995, 13:1152-1159.
23. Figgitt D.P., Wiseman L.R. Docetaxel: an update of its use in advanced breast cancer. Drugs 2000, 59:621-651.
24. Perez E.A. Paclitaxel in breast cancer. Oncologist 1998, 3:373-389.
25. Beslija S., Bonneterre J., Burstein H.J., Cocquyt V., Gnant M., Heinemann V., et al. Third consensus on medical treatment of metastatic breast cancer. Ann Oncol 2009, 20:1771-1785.